BIAF · bioAffinity Technologies, Inc.
$6.06
-0.09 (-1.46%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current expected level of operating expenditures, current expected levels of revenue, and the cash and cash equivalents on hand at June 30, 2026, of $2.4 million, management concludes that there is substantial doubt about our ability to continue as a going concern for a period of at least twelve (12) months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements contained in this Quarterly Report.”View the 10-Q filed Aug 7, 2026
Market Cap
$3.72M
Shares
540,115
Volume · Oct 2
154.64K
Avg daily vol (29 sessions)
6.44M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.06
Open$6.06
Day$5.90–6.24
52W close$4.56–71.10
Avg vol 30d6.2M
Short int71K · 13.2% float · 1.0d
Short vol39%
Last earningsApr 3, 2023
DataSep 2022–Oct 2026
Filing10-Q · Aug 7
Up next
filed Aug 7, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$5.90M
Trailing 12 months
Net income (TTM)
−$15.19M
Trailing 12 months
Revenue growth YoY
+19.0%
Year over year
Operating margin
-209.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+552.8%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
13.2%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−71%
below
Price vs 50-day avg
−21%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−53%
trailing
6-month return
−87%
trailing
YTD return
−66%
this year
Relative strength
−99%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $21 — 200d above 50d
Institutional flow
Accumulating
+29% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
13.18% of float · ▲ +61.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
22 holders — near 3-yr high, broad support
Squeeze score
58
elevated · 0–100
Fundamentals
Revenue growth
+14%
Y/Y
Gross margin
0%
EPS growth
+62%
Y/Y
Free cash flow
$-9.4M
Quant / Vol
risk profile
Volatility
209%
annualized · 1-yr
Max drawdown
−94%
past year
ATR
26.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Nov 15, 2023
Net revenues
· next 12 months (fourth quarter 2023 to third quarter 2024)
$8.4M – $9M
Guided vs delivered
· last 1 settled
Net revenues
2023
guided $2.1M – $2.3M
$2.53M
Beat +15.1%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−71%
Bearish
Price vs 50-day avg
−21%
Bearish
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $21 — 200d above 50d
Institutional flow
Accumulating
+29% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
13.18% of float · ▲ +61.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
22 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $6 · 2%
Range high $71
vs 200-day avg -71%
vs 50-day avg -21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Clinical sites for longitudinal CyPath Lung trial | 11 | Q2 2026 | — |
| CyPath Lung test reports delivered | 1,097 | Six months ended June 30, 2026 | — |
| CyPath Lung testing revenue | $835,000 | Six months ended June 30, 2026 | — |
| CyPath® Lung diagnostic test volume | 216% | Q2 2026 | — |
| CyPath® Lung test results delivered | 622 | the three months ended June 30, 2026 filing | — |
| Existing client CyPath Lung orders | 71% | Six months ended June 30, 2026 | — |
| Physician offices and clinics ordering CyPath Lung | 122% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BIAF
this stock
bioAffinity Technologies, Inc.
|
$3.72M | — | +14.5% | — | 13.2% |
|
TMO
Thermo Fisher Scientific Inc.
|
$249.58B | +13.0% | +14.5% | 36.3 | 1.4% |
|
DHR
Danaher Corp /De/
|
$150.37B | -6.5% | +8.5% | 37.9 | 1.2% |
|
NTRA
Natera, Inc.
|
$59.47B | +79.1% | -2.8% | — | 3.3% |
|
A
Agilent Technologies, Inc.
|
$48.90B | +23.3% | +6.4% | 34.2 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BIAF | -23.6% | -52.6% | -87.3% | -7.7% | -65.8% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -23.4% | -52.2% | -99.5% | -8.6% | -78.7% |